PROPHYLACTIC ORAL ANTICOAGULATION IN NEPHROTIC PATIENTS WITH IDIOPATHIC MEMBRANOUS NEPHROPATHY

被引:76
作者
SARASIN, FP [1 ]
SCHIFFERLI, JA [1 ]
机构
[1] UNIV GENEVA, SCH MED, CH-1211 GENEVA 4, SWITZERLAND
关键词
D O I
10.1038/ki.1994.75
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Whether the high incidence of thromboembolic events in nephrotic patients with membranous nephropathy justifies prophylactic administration of oral anticoagulants remains controversial. We used a Markov-based decision analysis model, explicitly considering the consequences of recurrent embolic and bleeding events to quantify the risk-benefit trade-offs of: (1) prophylactic therapy, in which oral anticoagulation was started at the time of diagnosis of nephrotic syndrome (before any thromboembolic event); and (2) anticoagulant therapy, in which treatment was started after the first clinical thromboembolic event. We assumed that anticoagulant therapy was discontinued if there was remission of the nephrotic syndrome. The overall number of fatal emboli prevented by prophylactic anticoagulants exceeded the one of fatal bleeding events for all clinically meaningful ranges of the following parameters: nephrotic syndrome duration, incidence of thromboembolic events, likelihood of embolization, and mortality rates of embolic and bleeding events. For a hypothetical 50-year-old patient who remained nephrotic for 2 years, prophylactic anticoagulation yielded a gain representing 2.5 months of quality-adjusted life expectancy. We conclude that for nephrotic patients with membranous nephropathy, the benefits of prophylactic administration or oral anticoagulants outweigh the risks.
引用
收藏
页码:578 / 585
页数:8
相关论文
共 32 条
[1]   A POPULATION-BASED PERSPECTIVE OF THE HOSPITAL INCIDENCE AND CASE-FATALITY RATES OF DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM - THE WORCESTER DVT STUDY [J].
ANDERSON, FA ;
WHEELER, HB ;
GOLDBERG, RJ ;
HOSMER, DW ;
PATWARDHAN, NA ;
JOVANOVIC, B ;
FORCIER, A ;
DALEN, JE .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (05) :933-938
[2]  
ANDRASSY K, 1980, KLIN WOCHENSCHR, V58, P399
[3]  
ARDILES L, 1989, REV MED CHILE, V117, P266
[4]   THE MARKOV PROCESS IN MEDICAL PROGNOSIS [J].
BECK, JR ;
PAUKER, SG .
MEDICAL DECISION MAKING, 1983, 3 (04) :419-458
[5]   CURRENT STATUS OF PULMONARY THROMBOEMBOLIC DISEASE - PATHO-PHYSIOLOGY, DIAGNOSIS, PREVENTION, AND TREATMENT [J].
BELL, WR ;
SIMON, TL .
AMERICAN HEART JOURNAL, 1982, 103 (02) :239-262
[6]   RENAL-VEIN THROMBOSIS IN NEPHROTIC SYNDROME [J].
BENNETT, WM .
ANNALS OF INTERNAL MEDICINE, 1975, 83 (04) :577-578
[7]  
Cameron J, 1988, NEPHROTIC SYNDROME, P849
[8]   THE CLINICAL COURSE OF PULMONARY-EMBOLISM [J].
CARSON, JL ;
KELLEY, MA ;
DUFF, A ;
WEG, JG ;
FULKERSON, WJ ;
PALEVSKY, HI ;
SCHWARTZ, JS ;
THOMPSON, BT ;
POPOVICH, J ;
HOBBINS, TE ;
SPERA, MA ;
ALAVI, A ;
TERRIN, ML .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (19) :1240-1245
[9]   VENOUS THROMBOEMBOLISM - SCOPE OF THE PROBLEM [J].
DALEN, JE ;
OCKENE, IS ;
HIRSH, J ;
ALPERT, JS .
CHEST, 1986, 89 (05) :S370-S373
[10]  
DELUCA M, 1991, AM J NEPHROL, V11, P260